Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(6 years from now) | |
US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(6 years from now) | |
US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) |
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8388941 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8323630 | NOVARTIS | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8268299 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(6 years from now) |
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic